An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau

Skåne University Hospital, Region Skåne0 个研究点目标入组 590 人开始时间: 2014年8月5日最近更新: 2024年7月29日

试验速览

暂无简介。

•The healthy controls should fulfil the following criteria i) at least 60 years of age ii) no cognitive symptoms, iii) MMSE score 28-30, iv) do not fulfil the criteria of mild cognitive impairment or dementia; v) no significant neurological or psychiatric disorder.
•The patients with mild cognitive symptoms should fulfil the following criteria: i) at least 60 years of age ii) mild cognitive symptoms, iii) MMSE score 24-30, iv) do not fulfil the criteria of dementia.
•The patients clinically diagnosed with a tauopathy” will be at least 50 years of age and they should fulfil the current clinical criteria of AD, FTD, PSP, CBD, PD, PDD, DLB, MSA or VaD.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 140
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 450

•The exclusion criteria of the present study are:
•- History of alcohol or substance abuse or dependence within the last five years.
•- Current major depressive disorder.
•- History of schizophrenia or other recurrent psychotic disorder.
•- Diseases that will make study participation difficult, such as metastatic cancer disease, severe renal or hepatic impairment or significant infectious disease.
•- Have received or participated in a trial with investigational medications in the past 30 days.

发起方

Skåne University Hospital, Region Skåne